You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe

Citation Tools

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ogando YM, Prabhu VS, Zhang J, et al
2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe
International Journal of Gynecologic Cancer 2022;32:A105-A106.